Revolutionary POSEIDON Project Aims to Detect 30+ Cancers Early Using Breath and Urine Tests
A groundbreaking initiative, POSEIDON, is developing non-invasive, multi-cancer early detection tests. These tests promise reliable early detection, non-invasive sample collection, digital healthcare system integration, and a low-cost model for wide adoption.
POSEIDON aims to create tests for over 30 solid tumours at Stage I using breath and urine samples. The project involves inhaling synthetic sensors that accumulate on cancer cells, producing detectable signals in breath or urine samples. These tests will be available for at-home use, sold over the counter, making cancer screening more accessible and affordable.
The POSEIDON programme is a collaboration between Owlstone Medical, MIT, Boston University, Georgia Tech, Qurin B.V., and Planned Systems International. The project is funded by ARPA-H, with up to £39.3 million secured by Owlstone Medical. Tests will use portable collection and analysis devices, with results automatically uploaded to electronic health records for rapid clinical review.
The POSEIDON programme seeks to deliver low-cost, accurate cancer screening to adults across the US, focusing on early detection and improved survival rates. The non-invasive, at-home tests promise to revolutionise cancer screening, making it more accessible and affordable.
